Article3 Biotech2023
In vitro and in vivo investigation of chrysin chelated copper complex as biocompatible materials for bone tissue engineering applications.
Article in 3 Biotech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Chrysin: A Comprehensive Review of Its Pharmacological Properties and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring the Correlation Between the Molecular Structure and Biological Activities of Metal-Phenolic Compound Complexes: Research and Description of the Role of Metal Ions in Improving the Antioxidant Activities of Phenolic Compounds.International journal of molecular sciences · 2024Review
- Copper metabolism in osteoarthritis and its relation to oxidative stress and ferroptosis in chondrocytes.Frontiers in molecular biosciences · 2024Review
- Evaluation of chrysin incorporated chitosan-based scaffold for bone regeneration in rat models.Journal of Indian Society of PeriodontologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoid metal complexes have interesting properties and are widely explored for bone regeneration owing to their potent biological activity. In the present study, we investigated the biocompatibility and osteogenic properties of the Copper(II)-chrysin complex (C/Cu). The biocompatibility of C/Cu was assessed in vitro with human osteoblastic cells and in vivo using chick embryo and zebrafish models. The C/Cu complex was found to be cytofriendly with good biocompatibility. The osteogenic property of C/Cu was studied at cellular and molecular levels. C/Cu promoted mineralization in osteoblastic cultures by increasing ALP activity. At the molecular level, C/Cu significantly promoted the mRNA levels of osteoblast differentiation marker genes such as runt-related transcription factor 2 (Runx2), Type 1 collagen and ALP. In addition to this, secretory proteins, osteonectin (ON) and osteocalcin (OC) levels were also stimulated. We have also identified that C/Cu exhibited enhanced osteogenic properties and antibacterial activity compared with Chrysin. Thus, C/Cu can be used as an osteogenic agent in bone tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.